

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS EO Box 150 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/912,968 07/25/2001 Stanton B. Dotson 38-21(51862)B 6793 7590 08/26/2003 Lawrence M. Lavin, Jr. EXAMINER Patent Department, E2NA SHEINBERG, MONIKA B Monsanto Company 800 N. Lindbergh Boulevard St. Louis, MO 63167 ART UNIT PAPER NUMBER 1634

DATE MAILED: 08/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	1	A 1: 1/-)
	Application No.	Applicant(s)
Office Action Summary	09/912,968	DOTSON ET AL.
	Examiner	Art Unit
	Monika B Sheinberg	1634
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a re y within the statutory minimum of thirty will apply and will expire SIX (6) MONT cause the application to become AB	rply be timely filed r (30) days will be considered timely. "HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on		
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims	ın.	
 4) ☐ Claim(s) 35-50 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 		
5)∐ Claim(s) is/are allowed. 6)∐ Claim(s) is/are rejected.		
7)∐ Claim(s) is/are objected to. 8)⊠ Claim(s) <u>35-50</u> are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examine	r.	
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12)☐ The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) All b) Some * c) None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.		
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Ir	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152) It is ailed Action .

Application/Control Number: 09/912,968

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121: (Please note that the replacement claims 1-16 are entered as claim numbers 35-50.)

- I. Claims 35-50, drawn to a method to detect expression of a transgenic nucleic acid molecule in a sample using hybridization to a 3' untranslated sequence from the 3' end of the *Pisum sativum* rbcS E9 gene (SEQ ID NO: 2) and its corresponding oligonucleotide (one of SEQ ID NO: 7-12, 26-28), classified in class 435, subclass 6.
- II. Claims 35-50, drawn to a method to detect expression of a transgenic nucleic acid molecule in a sample using hybridization to a Petunia HSP70 5' untranslated leader sequence (SEQ ID NO: 5) and its corresponding oligonucleotide (one of SEQ ID NO: 7-12, 26-28), classified in class 435, subclass 6.
- III. Claims 35-50, drawn to a method to detect expression of a transgenic nucleic acid molecule in a sample using hybridization to a wheat fructose 1,6-biphosphatase 5' untranslated leader (SEQ ID NO: 32) and its corresponding oligonucleotide (one of SEQ ID NO: 7-12, 26-28), classified in class 435, subclass 6.
- IV. Claims 35-50, drawn to a method to detect expression of a transgenic nucleic acid molecule in a sample using hybridization to a 3' untranslated sequence from the wheat ubiquitin gene (SEQ ID NO: 33) and its corresponding oligonucleotide (one of SEQ ID NO: 7-12, 26-28), classified in class 435, subclass 6.
- V. Claims 35-50, drawn to a method to detect expression of a transgenic nucleic acid molecule in a sample using hybridization to a 3' untranslated sequence from the nopaline synthase gene (SEQ ID NO: 35) and its corresponding oligonucleotide (one of SEQ ID NO: 7-12, 26-28), classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

Each Group (I-V) detailed above reads on patentably distinct sequences. Each sequence is patentably distinct because they are unrelated sequences, and a restriction is applied to each

Application/Control Number: 09/912,968

Art Unit: 1634

Group. (See MPEP 803.04). It is noted that this is a restriction requirement to a single sequence and NOT a specie election requirement.

MPEP 803.04 states:

"Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions with the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq."

It has been determined that 1(ONE) sequence constitutes a reasonable number for examination purposes under the present conditions. At present the huge number of submissions of claims directed to various sequences, such as nucleic acids or polypeptides, is so large that the election of 1(one) sequence of this type is now deemed to be practically appropriate so as to not overwhelm the examination and search processes for such claims.

Examination will be restricted to only the elected sequence.

Conclusion

A telephone call was made to Lawrence Lavin on 25 August 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Inquiries

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096

Application/Control Number: 09/912,968

Art Unit: 1634

OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Monika B. Sheinberg, whose telephone number is (703) 306-0511. The examiner can normally be reached on Monday-Friday from 9 A.M to 5 P.M. If attempts to reach the examiner by telephone are unsuccessful, the primary examiner in charge of the prosecution of this case, Jehanne Souaya, can be reached at 703-308-6565. If attempts to reach the examiners are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Patent Analyst, Chantae Dessau, whose telephone number is (703) 605-1237, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

August 25, 2003 Monika B. Sheinberg Art Unit 1634

435

Jehanne Souaya Jehanne souaya Patent ey angineed Page 4

8/25/03